Moderate- versus high-activity radioactive iodine in intermediate-risk papillary thyroid cancer: a Canadian cohort study
Journal of the Endocrine Society · 03.06.2026 · 10 (7)
DOI: 10.1210/jendso/bvag066 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the Endocrine Society, online erschienen am 24.03.2026. Verfasst von Mohammad Jay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
The optimal radioactive iodine (RAI) activity for intermediate-risk papillary thyroid cancer (PTC) remains uncertain, and evidence to guide individualized treatment is limited.
Objective
To compare recurrence between moderate- and high-activity RAI and to identify clinicopathologic factors associated with persistent or recurrent disease.
Methods
We conducted a retrospective cohort study of adults with intermediate-risk PTC treated at a tertiary academic thyroid cancer clinic between 2010 and 2022. Patients received moderate-activity RAI, defined as 30 to 90 mCi, or high-activity RAI, defined as greater than 90 mCi, as initial postoperative therapy. The primary outcome was time to recurrence. The secondary outcome was a composite of persistent or recurrent disease at last follow-up.
Results
Among 181 patients, 94 received moderate-activity RAI and 87 received high-activity RAI. Over a median follow-up of 52 months, 18 recurrences occurred (crude: 3/94 vs 15/87). High-activity RAI was not associated with improved recurrence-free survival (inverse probability of treatment weighting [IPTW]-weighted hazard ratio 2.73; 95% confidence interval [CI] 0.74 to 10.01). Persistent or recurrent disease occurred in 61 patients (34%) with no association in IPTW models (hazard ratio 0.97; 95% CI 0.53 to 1.76). Extranodal extension, microscopic extrathyroidal extension, larger lymph node deposit size, and older age were associated with persistent or recurrent disease.
Conclusion
High-activity RAI was not associated with improved recurrence versus moderate-activity in intermediate-risk PTC. This study is among the first to evaluate moderate-activity RAI as a distinct comparator. Findings support moderate-activity RAI as a reasonable risk-adapted approach. Prospective studies are needed to validate these results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
- Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada.
ORCID-Profile: Mohammad Jay
Zitieren
APA
Jay, M., Lega, I. C., Villemure-Poliquin, N., Goens, C., & Zahedi, A. (2026). Moderate- versus high-activity radioactive iodine in intermediate-risk papillary thyroid cancer: a Canadian cohort study. Journal of the Endocrine Society, 10(7). https://doi.org/10.1210/jendso/bvag066
Vancouver
Jay M, Lega IC, Villemure-Poliquin N, Goens C, Zahedi A. Moderate- versus high-activity radioactive iodine in intermediate-risk papillary thyroid cancer: a Canadian cohort study. Journal of the Endocrine Society. 2026;10(7). doi:10.1210/jendso/bvag066
BibTeX
@article{Jay2026,
author = {Jay, Mohammad and Lega, Iliana C and Villemure-Poliquin, Noemie and Goens, Cristina and Zahedi, Afshan},
title = {Moderate- versus high-activity radioactive iodine in intermediate-risk papillary thyroid cancer: a Canadian cohort study},
journal = {Journal of the Endocrine Society},
year = {2026},
volume = {10},
number = {7},
doi = {10.1210/jendso/bvag066}
}
EUVIMED